At diagnosis : DNA test, PCR and capillary electrophoresis. Multiplex assay with NPM1 and CEBPalpha mutation analysis. Consensus primers from working group MolecularDiagnostics.be.
Version date: 04/11/2017 Accredited:
UZA Mol. Diagn.
FLT3-ITD mutation analysis
K. Vermeulen,
M. Le Mercier,
M-B Maes
PCR on DNA followed by fragment analysis. Consensus primers from working group MolecularDiagnostics.be.
TAT: max 8 days
Sample Type: Blood, Bone marrow
Version date: 30/07/2019 Accredited:
Jessa Hospital
FLT3-ITD mutation analysis
Dr. Brigitte Maes, Femke Hillen
SAMPLE TYPE:
Blood or bone marrow (1ml, EDTA)
TRANSPORT: room temperature
FREQUENCY: 1x/week
TEST TYPE: Only at diagnosis or relapse: DNA test, PCR and capillary electrophoresis. Multiplex assay with NPM1 mutation analysis. Consensus primers from working group MolecularDiagnostics.be.
UZ Leuven MolPLUZ
FLT3-ITD mutation analysis
Lucienne Michaux / Els Lierman
Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 2x/week
Test type: PCR on DNA, adapted from Noguera et al, Leukemia 2008.
Accredited:
AZ Delta
FLT3-ITD mutation analysis
Geert Martens, Elke Boone
SAMPLE TYPE: blood or bone marrow (1 ml)
FREQUENCY: upon request, at diagnosis or relapse
TEST TYPE: DNA test, PCR and capillary electrophoresis. Multiplex assay with CEBPA and NPM1 mutation analysis. Consensus primers from working group MolecularDiagnostics.be.
Version date: 05/12/2017 Accredited:
UZ Gent
FLT3-ITD mutation analysis
Barbara Denys,
Karl Vandepoele
Quick, simultaneous detection with NPM1, FLT3-TKD and CEBPA (capillary electrophoresis)
DNA test
TAT: 8 days
Version date: 25/09/2018 Accredited: